Biostatistics/Bioinformatics Core

生物统计学/生物信息学核心

• 批准号: 8712175
• 负责人: Li-Xuan Qin
• 金额: $ 9.09万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至 2018-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8712175
• 关键词: Address; Bioinformatics; Biometry; Characteristics; Clinical Research; Clinical Trials; Clinical Trials Design; Collaborations; Cox Proportional Hazards Models; DNA copy number; Data; Data Analyses; Drug Formulations; Experimental Designs; Genetic Transcription; Genomics; Human; Laboratories; Laboratory Research; Memorial Sloan-Kettering Cancer Center; Messenger RNA; Methodology; Methods; MicroRNAs; Molecular; Molecular Profiling; Mutation; Outcome; Pathway Analysis; Pathway interactions; Pharmaceutical Preparations; Phase; Phenotype; Population; Principal Investigator; Procedures; Protocols documentation; Randomized; Research; Research Personnel; Risk; Sample Size; Sampling; Testing; anticancer research; base; design; member; molecular scale; preclinical study; primary outcome; research study; response; sarcoma; soft tissue; tool; tumor; tumorigenesis

The Biostatistics & Bioinformatics Core will support investigators of the SPORE in Soft Tissue Sarcoma in the computational and statistical aspects of their research efforts, including the design and analysis of clinical trials, laboratory experiments, molecular profiling, and sequencing, as well as integrated genomic analyses. In the clinical trial design phase, a core member will conduct a protocol review with the principal investigator. Based on this review, a statistical section for the protocol will be provided, outlining major scientific objectives, population to be studied, primary and secondary endpoints, experimental design, analysis plans, and a targeted sample size justified in probabilistic terms. At the conclusion of the trial, data analyses will be performed to assess outcomes of the primary and secondary endpoints stated in the protocol. In preclinical studies, core members will assist in the formulation of the experimental design and in the analysis and interpretation of the data at the conclusion of the study. The core will also assist in the large-scale molecular characterization of human sarcoma samples, which involves analyzing RNA expression, microRNA expression, mutations, and DNA copy number changes to identify predictors of tumor characteristics, drug response, and survival. Core members will use two-sample t-tests and Cox proportional hazards models to identify informative features. The different types of molecular data will be integrated and pathway analysis performed to elucidate the pathways that contribute to tumorigenesis and tumor phenotype. Risk prediction tools will be developed using Cox proportional hazards models based on these features.

生物统计学和生物信息学核心将在其研究工作的计算和统计方面支持软组织肉瘤中孢子的研究者，包括对临床试验，实验室实验，分子分析和测序的设计和分析，以及集成的基因组分析。在临床试验设计阶段，核心成员将与首席研究员进行协议审查。基于此综述，将提供有关该协议的统计部分，概述了主要的科学目标，要研究的人群，主要和次要终点，实验设计，分析计划以及针对性的样本量，以概率术语为合理。在试验结束时，将进行数据分析，以评估协议中所述的主要和次要终点的结果。在临床前研究中，核心成员将协助制定实验设计，并在研究结束时对数据的分析和解释。核心还将有助于人类肉瘤样品的大规模分子表征，其中涉及分析RNA表达，microRNA表达，突变和DNA拷贝数的变化，以识别肿瘤特征，药物反应和存活率的预测指标。核心成员将使用两样本的t检验和COX比例危害模型来确定内容丰富的功能。将整合不同类型的分子数据，并进行途径分析以阐明有助于肿瘤发生和肿瘤表型的途径。风险预测工具将使用基于这些功能的COX比例危害模型开发。